Skip to content

Postoperative Analgesia of Magnesium Sulfate in Suprascapular Nerve Block Following Shoulder Arthroscopy

Efficacy of Magnesium Sulfate Added to Bupivacaine in Suprascapular Nerve Block on Duration of Analgesia Following Shoulder Arthroscopy: a Prospective Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03602469
Enrollment
60
Registered
2018-07-26
Start date
2018-07-31
Completion date
2019-01-31
Last updated
2018-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroscopic Shoulder Surgery

Brief summary

* Arthroscopic shoulder surgeries in adults are accompanied with severe immediate postoperative pain reported in approximately 45% of patients. For quicker recovery and rehabilitation of these patients, postoperative analgesia is mandatory. * Different analgesic modalities have been proposed including parenteral opioids, intra-articular injection of local anesthetics, interscalene brachial plexus block (ISB), and a suprascapular nerve block (SSNB), with varying degrees of effectiveness and multiple reported side effects. * A recent meta-analysis demonstrates that suprascapular block results in 24-h morphine consumption and pain scores similar to ISB, so, it may be considered an effective and safe alternative for interscalene block in shoulder surgery, with less motor restriction, and fewer complications. * Different agents are used as adjuvants to local anesthetics during peripheral nerve block to prolong its analgesic action including magnesium sulfate. * A meta-analysis by Mengzhu et al., concluded that magnesium sulfate combined with local anesthetics in perineural nerve blocks provided better analgesic efficacy and may be a promising analgesic for perineural nerve blocks. * Antinociceptive effects of magnesium are due to the regulation of calcium influx into the cell and a non-competitive antagonism of the NMDA receptors

Detailed description

The aim of this study is to evaluate the effects of magnesium sulfate as an adjuvant to bupivacaine in suprascapular nerve block on the duration and quality of postoperative analgesia following shoulder arthroscopy, postoperative pain VAS scores, intraoperative fentanyl requirements, sedation scores, respiratory depression, postoperative 24 hours cumulative morphine consumption.

Interventions

DRUGBupivacaine

Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline

DRUGBupivacaine-magnesium

Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)

DRUGPropofol

Using propofol 1.5-2.5 mg/kg

DEVICEUltrasound

Ultrasound-guided suprascapular nerve block

DRUGSevoflurane

Sevoflurane 0.7-1.5 MAC in 40% oxygen

DRUGRocuronium

Rocuronium 0.6 mg/kg

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Double-blind study

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ASA physical status I-III

Exclusion criteria

* Patient's refusal * Significant cardiac diseases * Significant hepatic diseases * Significant renal diseases (serum creatinine ˃ 1.5 mg/dl) * Cardiac conduction abnormalities * Drug abuse * Pregnancy * Allergy to study medications * Mental disease * Communication barrier * Coagulopathy * Local skin infection * Traumatic nerve injury of upper limb * Patients receiving opioid analgesics * Patients receiving magnesium sulfate * Patients receiving beta blockers * Patients receiving calcium channel blockers * Previous shoulder surgery

Design outcomes

Primary

MeasureTime frameDescription
Duration of postoperative analgesiaFor 8 hours after suprascapular nerve blocktime from administering the study solution in the suprascapular block till the time for the first rescue morphine request

Secondary

MeasureTime frameDescription
Pain score on shoulder abductiontime 0 (after extubating) and at 30 minutes, 1 hour , 2 hours, 4hours, 6hours, 8hours,12 hours , 16hours, 20 hours and 24 hours postoperativelyPain score as assessed using visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and 100 mm for worst imaginable pain)
Systolic arterial blood pressureAt baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery , every 6 hours up to 24 hours postoperatively
Diastolic arterial blood pressureAt baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery , every 6 hours up to 24 hours postoperatively
Heart rateAt baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery ,every 6 hours up to 24 hours postoperatively
Intraoperative fentanyl requirementsFor 5 hours after suprascapular nerve block
Pain score at resttime 0 (after extubating) and at 30 minutes, 1 hour , 2 hours, 4hours, 6hours, 8hours,12 hours , 16hours, 20 hours and 24 hours postoperativelyPain score as assessed using visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and 100 mm for worst imaginable pain)
The degree of nausea and vomitingFor 24 hours after surgeryNausea will be measured using a numerical rating system (none= 0; mild= 1; moderate= 2; severe= 3)
Number of vomiting episodesFor 24 hours after surgery
Number of antiemetics receivedFor 24 hours after surgery
Postoperative cumulative morphine consumptionFor 24 hours after surgery
Sedation scoresat 1 hour, 2 hours, and 6 hours postoperativelySedation: will be assessed using a sedation scale (awake and alert= 0; quietly awake= 1; asleep but easily roused= 2; deep asleep= 3).

Countries

Egypt

Contacts

Primary ContactHanaa M Elbendary, MD
hanaa_elbendary@yahoo.com00201005781768
Backup ContactSamah El Kenany, MD
sk_20022000@yahoo.com00201002262557

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026